CA2302630A1 - Acyclonucleosides de purine utilises comme agents antiviraux - Google Patents

Acyclonucleosides de purine utilises comme agents antiviraux Download PDF

Info

Publication number
CA2302630A1
CA2302630A1 CA002302630A CA2302630A CA2302630A1 CA 2302630 A1 CA2302630 A1 CA 2302630A1 CA 002302630 A CA002302630 A CA 002302630A CA 2302630 A CA2302630 A CA 2302630A CA 2302630 A1 CA2302630 A1 CA 2302630A1
Authority
CA
Canada
Prior art keywords
hydroxy
amino
hydrogen
compound
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002302630A
Other languages
English (en)
Inventor
Karen Elizabeth Jarvis
Sebastian Mario Marcuccio
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Commonwealth Scientific and Industrial Research Organisation
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2302630A1 publication Critical patent/CA2302630A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/36—Sulfur atom

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne l'utilisation dans le traitement ou la prophylaxie de l'infection virale de l'hépatite B, d'un composé de la formule (1) ou un sel ou des dérivés pharmaceutiquement acceptables dudit composé. Dans cette formule, R?1¿ désigne hydrogène, halogène, hydroxy, azido, alcoxy, arylthyo, aryloxy, thio, alkylthio, amino, alkylamino, hydrazino, hydroxylamino, benzyloxy, NRR' ou NRCOR'; R?2¿ désigne hydrogène, halogène, hydroxy, azido, alcoxy, aryloxy, thio, alkylthio, amino, alkylamino, hydrazino, hydroxylamino, benzyloxy, NRR' ou NRCOR'; et R et R' sont sélectionnés indépendamment l'un de l'autre dans le groupe comprenant hydrogène, alkyle et aryle.
CA002302630A 1997-09-11 1998-09-11 Acyclonucleosides de purine utilises comme agents antiviraux Abandoned CA2302630A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPO9129 1997-09-11
AUPO9129A AUPO912997A0 (en) 1997-09-11 1997-09-11 Antiviral agents
PCT/AU1998/000748 WO1999012927A1 (fr) 1997-09-11 1998-09-11 Acyclonucleosides de purine utilises comme agents antiviraux

Publications (1)

Publication Number Publication Date
CA2302630A1 true CA2302630A1 (fr) 1999-03-18

Family

ID=3803414

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002302630A Abandoned CA2302630A1 (fr) 1997-09-11 1998-09-11 Acyclonucleosides de purine utilises comme agents antiviraux

Country Status (9)

Country Link
EP (1) EP1019404A4 (fr)
JP (1) JP2001515900A (fr)
KR (1) KR20010023890A (fr)
CN (1) CN1269801A (fr)
AU (1) AUPO912997A0 (fr)
CA (1) CA2302630A1 (fr)
ID (1) ID26937A (fr)
NZ (1) NZ502994A (fr)
WO (1) WO1999012927A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI20022A (sl) * 1998-07-29 2000-02-29 Kemijski inštitut Alkilno substituirani purinovi derivati in njihova priprava
KR100377138B1 (ko) * 1998-11-10 2003-06-12 주식회사 엘지생명과학 퓨린구조를갖는싸이클린의존키나아제저해제,그제조방법및그를함유하는항암제조성물
GB9903762D0 (en) 1999-02-18 1999-04-14 Novartis Ag Organic compounds
WO2001076531A2 (fr) * 2000-04-07 2001-10-18 University Of Maryland, Baltimore Promedicaments contenant un acide biliaire et presentant une meilleure biodisponibilite
EP1440072A4 (fr) 2001-10-30 2005-02-02 Conforma Therapeutic Corp Analogues de purine presentant une activite inhibitrice de hsp90
JP2005535631A (ja) * 2002-06-27 2005-11-24 エフ．ホフマン−ラ　ロシュ　アーゲー プリン誘導体の合成
AU2004232392A1 (en) * 2003-04-21 2004-11-04 Ustav Organicke Chemie A Biochemie Akademie Ved Ceske Republiky (Purin-6-yl) amino acid and production method thereof
NZ546611A (en) 2003-09-18 2010-02-26 Conforma Therapeutics Corp Novel heterocyclic compounds as HSP90-inhibitors
BRPI0609509A2 (pt) 2005-03-30 2010-04-13 Conforma Therapeutics Corp composto ou um polimorfo, solvato, tautÈmero, enanciÈmero, pró-droga ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso do composto, polimorfo, solvato, tautÈmero, enanciÈmero, pró-droga ou sal farmaceuticamente aceitável
CN102002043B (zh) * 2010-11-16 2012-10-24 江苏科技大学 4-氨基吡啶催化下的6-甲氧基嘌呤衍生物的合成方法
CN102633767B (zh) * 2012-04-09 2013-10-30 武汉工程大学 一种非离子型碘造影剂中间体2－异丙基－5－羧基－1，3－二氧六环的制备方法
RU2751349C2 (ru) * 2016-08-29 2021-07-13 Ф. Хоффманн-Ля Рош Аг 7-замещенные сульфонимидоилпуриноны для лечения и профилактики вирусной инфекции

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5216141A (en) * 1988-06-06 1993-06-01 Benner Steven A Oligonucleotide analogs containing sulfur linkages
GB8904855D0 (en) * 1989-03-03 1989-04-12 Beecham Group Plc Pharmaceutical treatment

Also Published As

Publication number Publication date
NZ502994A (en) 2001-12-21
EP1019404A1 (fr) 2000-07-19
KR20010023890A (ko) 2001-03-26
AUPO912997A0 (en) 1997-10-02
ID26937A (id) 2001-02-22
EP1019404A4 (fr) 2001-07-04
CN1269801A (zh) 2000-10-11
JP2001515900A (ja) 2001-09-25
WO1999012927A1 (fr) 1999-03-18

Similar Documents

Publication Publication Date Title
RU2067097C1 (ru) Способ получения дидезоксидидегидрокарбоциклических нуклеозидов
AU2007212648B2 (en) Inhibitors of E1 activating enzyme
EP0329348B1 (fr) Nucléosides-2',3'-didéoxy-2',2'-difluoro
EA004983B1 (ru) Производные 2-аминокарбонил-9h-пурина
CA1276635C (fr) Les 9-(2-(hydroxymethyl)cyclokylmethyl)guanines
CS203093B2 (en) Method of preparing substituted purines
SK18192001A3 (sk) Deriváty purínu
KR20120092153A (ko) 바이러스 감염 치료를 위한 ２＇?플루오로?６＇?메틸렌 카보사이클릭 뉴클레오사이드 및 방법
JP2001509483A (ja) サイクリン依存性キナーゼ阻害性プリン誘導体
WO1996002543A1 (fr) Derives 2,3-dihydroxycyclopentane de purines
MXPA97002488A (en) Compounds of purine and guanine as inhibitors of
HU203755B (en) Process for producing cyclopenentyl-purine derivatives and pharmaceutical compositions containing them
HUT59152A (en) Process for producing cyclic analogs of nucleosides and pharmaceutical compositions comprising same as active ingredient
JP2722215B2 (ja) 新規なアリステロマイシン／アデノシン誘導体類
WO1999012927A1 (fr) Acyclonucleosides de purine utilises comme agents antiviraux
US20090270431A1 (en) Cyclopentenol Nucleoside Compounds Intermediates for their Synthesis and Methods of Treating Viral Infections
EP0242482A2 (fr) Composés purines et procédé de préparation
CA2944122A1 (fr) Derives d'acide sialique
CA2098876A1 (fr) Nucleosides a base de derives de substitution en 2,6,8 de 2'-desoxy-2',2-difluoropurine possedant une activite antivirale et anticancerigene; produits intermediaires
EP0366385B1 (fr) Dérivés de guanine ayant une activité anti-virale et leurs sels pharmaceutiquement acceptables
AU740264C (en) Antiviral agents
JP2013513552A (ja) 非環式ヌクレオシドホスホネート誘導体とその医療用途
US20170218001A1 (en) Phosphonate nucleosides useful in the treatment of viral diseases
Koszytkowska-Stawińska et al. Synthesis of aza-analogues of Ganciclovir
JPS635392B2 (fr)

Legal Events

Date Code Title Description
FZDE Discontinued